CN106432508A - 一种pla2r‑thsd7a融合蛋白及其应用和试剂盒 - Google Patents
一种pla2r‑thsd7a融合蛋白及其应用和试剂盒 Download PDFInfo
- Publication number
- CN106432508A CN106432508A CN201610770500.2A CN201610770500A CN106432508A CN 106432508 A CN106432508 A CN 106432508A CN 201610770500 A CN201610770500 A CN 201610770500A CN 106432508 A CN106432508 A CN 106432508A
- Authority
- CN
- China
- Prior art keywords
- fusion protein
- pla2r
- thsd7a
- sample
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JAPMJSVZDUYFKL-UHFFFAOYSA-N C1C2C1CCC2 Chemical compound C1C2C1CCC2 JAPMJSVZDUYFKL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
编号 | 1 | 2 | 3 | 4 | 5 |
A | 0.038 | 0.039 | 0.055 | 0.058 | 0.035 |
B | 0.038 | 0.04 | 0.048 | 0.04 | 0.058 |
C | 0.054 | 0.038 | 0.041 | 0.044 | 0.049 |
D | 0.058 | 0.034 | 0.042 | 0.043 | 0.056 |
E | 0.033 | 0.035 | 0.04 | 0.031 | 0.043 |
F | 0.044 | 0.038 | 0.046 | 0.038 | 0.054 |
G | 0.034 | 0.045 | 0.045 | 0.042 | 0.042 |
H | 0.05 | 0.035 | 0.05 | 0.065 | 0.046 |
编号 | 1 | 2 | 3 | 4 | 5 |
A | 0.699 | 0.723 | 0.348 | 0.747 | 0.553 |
B | 0.469 | 0.345 | 0.343 | 1.207 | 0.35 |
C | 0.684 | 1.513 | 0.497 | 1.496 | 0.271 |
D | 0.322 | 0.327 | 0.206 | 0.394 | 0.326 |
E | 0.318 | 0.477 | 0.393 | 0.337 | 0.304 |
F | 0.478 | 0.818 | 0.684 | 0.338 | 0.27 |
G | 0.334 | 0.21 | 0.504 | 0.93 | 0.379 |
H | 1.045 | 1.487 | 0.421 | 0.281 | 0.764 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610770500.2A CN106432508B (zh) | 2016-08-30 | 2016-08-30 | 一种pla2r‑thsd7a融合蛋白及其应用和试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610770500.2A CN106432508B (zh) | 2016-08-30 | 2016-08-30 | 一种pla2r‑thsd7a融合蛋白及其应用和试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106432508A true CN106432508A (zh) | 2017-02-22 |
CN106432508B CN106432508B (zh) | 2017-12-05 |
Family
ID=58091031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610770500.2A Active CN106432508B (zh) | 2016-08-30 | 2016-08-30 | 一种pla2r‑thsd7a融合蛋白及其应用和试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106432508B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107663235A (zh) * | 2017-08-11 | 2018-02-06 | 南京诺唯赞医疗科技有限公司 | 特发性膜性肾病相关的pla2r重组蛋白及其应用 |
CN108948181A (zh) * | 2018-07-05 | 2018-12-07 | 睿诺医疗科技(上海)有限公司 | 一种磷脂酶a2受体蛋白的制备方法 |
CN111413506A (zh) * | 2018-01-30 | 2020-07-14 | 深圳市伯劳特生物制品有限公司 | 一种检测试纸条在制备检测pla2r抗体的试剂盒中的应用 |
CN111413501A (zh) * | 2018-01-30 | 2020-07-14 | 深圳市伯劳特生物制品有限公司 | 一种检测试纸条在制备检测thsd7a抗体的试剂盒中的应用 |
CN112111015A (zh) * | 2020-09-24 | 2020-12-22 | 四川携光生物技术有限公司 | PLA2R、C1q、THSD7A融合蛋白及其构建方法、应用 |
CN116199795A (zh) * | 2022-03-29 | 2023-06-02 | 成都地奥制药集团有限公司 | 融合蛋白及其用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101735321A (zh) * | 2008-11-27 | 2010-06-16 | 上海荣盛生物药业有限公司 | 多肽组合物及其在结核病抗体检测中的应用 |
CN104193827A (zh) * | 2014-09-01 | 2014-12-10 | 山东莱博生物科技有限公司 | 一种丙型肝炎病毒第一高变区融合抗原及其应用 |
EP2977758A1 (en) * | 2014-07-24 | 2016-01-27 | Université De Nice Sophia Antipolis | Methods and kits for monitoring membranous nephropathy |
-
2016
- 2016-08-30 CN CN201610770500.2A patent/CN106432508B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101735321A (zh) * | 2008-11-27 | 2010-06-16 | 上海荣盛生物药业有限公司 | 多肽组合物及其在结核病抗体检测中的应用 |
EP2977758A1 (en) * | 2014-07-24 | 2016-01-27 | Université De Nice Sophia Antipolis | Methods and kits for monitoring membranous nephropathy |
CN104193827A (zh) * | 2014-09-01 | 2014-12-10 | 山东莱博生物科技有限公司 | 一种丙型肝炎病毒第一高变区融合抗原及其应用 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107663235A (zh) * | 2017-08-11 | 2018-02-06 | 南京诺唯赞医疗科技有限公司 | 特发性膜性肾病相关的pla2r重组蛋白及其应用 |
CN111413506A (zh) * | 2018-01-30 | 2020-07-14 | 深圳市伯劳特生物制品有限公司 | 一种检测试纸条在制备检测pla2r抗体的试剂盒中的应用 |
CN111413501A (zh) * | 2018-01-30 | 2020-07-14 | 深圳市伯劳特生物制品有限公司 | 一种检测试纸条在制备检测thsd7a抗体的试剂盒中的应用 |
CN108948181A (zh) * | 2018-07-05 | 2018-12-07 | 睿诺医疗科技(上海)有限公司 | 一种磷脂酶a2受体蛋白的制备方法 |
CN112111015A (zh) * | 2020-09-24 | 2020-12-22 | 四川携光生物技术有限公司 | PLA2R、C1q、THSD7A融合蛋白及其构建方法、应用 |
CN112111015B (zh) * | 2020-09-24 | 2021-12-07 | 苏州携创生物技术有限公司 | PLA2R、C1q、THSD7A融合蛋白及其构建方法、应用 |
CN116199795A (zh) * | 2022-03-29 | 2023-06-02 | 成都地奥制药集团有限公司 | 融合蛋白及其用途 |
WO2023185957A1 (zh) * | 2022-03-29 | 2023-10-05 | 成都地奥制药集团有限公司 | 抗体、融合蛋白及其用途 |
Also Published As
Publication number | Publication date |
---|---|
CN106432508B (zh) | 2017-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106432508B (zh) | 一种pla2r‑thsd7a融合蛋白及其应用和试剂盒 | |
CN113557431A (zh) | 诊断SARS-CoV-2感染的方法和试剂 | |
CN102057277A (zh) | 大麻使用的检测 | |
CN105384803B (zh) | 一种日本血吸虫重组蛋白SjSAPLP4及其编码基因与应用 | |
CN111521816B (zh) | 牛细粒棘球蚴病时间分辨荧光免疫层析检测试纸条及其制备方法 | |
CN105542014B (zh) | Tp重组抗原及其制备方法和应用 | |
CN105399827A (zh) | Wasabi蛋白纳米抗体及其编码序列与应用 | |
CN107643405A (zh) | 一种检测抗tsc22d3等血液自身抗体的肺癌诊断试剂盒和检测方法及其应用 | |
CN111999492A (zh) | 一种联合检验covid-19n抗原和s蛋白抗体的胶体金免疫层析检测卡 | |
CN102221616B (zh) | 一种鸡毒支原体间接elisa诊断试剂盒 | |
CN104215761A (zh) | 检测血清中抗gp73抗体的试剂盒 | |
CN114152748A (zh) | 一种检测非洲猪瘟病毒的双抗体夹心elisa诊断试剂盒及其方法 | |
CN111087453A (zh) | 一种肺炎衣原体重组抗原的制备方法及其应用方法 | |
CN109239341B (zh) | 一种牛溶血性曼氏杆菌抗体检测的间接elisa试剂盒及其应用 | |
EP2884277A1 (en) | Pivka-ii measurement method, measurement reagent, and measurement kit | |
CN111796090B (zh) | 牛细粒棘球蚴病时间分辨荧光免疫层析检测试纸条及其制备方法 | |
CN107860927A (zh) | 一种过敏原Pru p1蛋白的制备方法和检测试剂盒及其检测方法 | |
CN105254732B (zh) | 一种日本血吸虫重组蛋白SjSAPLP5及其编码基因与应用 | |
CN111596070A (zh) | 一种三疣梭子蟹原肌球蛋白过敏检测试剂的应用 | |
CN106939034A (zh) | 用于鉴定受试者所感染的hev基因型的方法和试剂盒 | |
CN104459127B (zh) | 生物载体及其在检测中的应用 | |
CN106632618A (zh) | 一种猪戊型肝炎病毒orf2重组蛋白的制备方法及其orf2蛋白和检测试剂盒 | |
CN114720691B (zh) | 一种检测生物标志物的试剂盒及其制备方法和应用 | |
CN109679970A (zh) | 猫疱疹i型病毒快速检测的制备方法 | |
CN105037555B (zh) | 缀合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Xiong Zuying Inventor after: Wang Hongtao Inventor after: Lin Jun Inventor after: Liu Yao Inventor after: Zhang Yongding Inventor after: Zhang Dazhun Inventor after: Zhang Qiao Inventor after: Ma Weimin Inventor before: Xiong Zuying Inventor before: Wang Hongtao Inventor before: Lin Jun Inventor before: Liu Yao Inventor before: Zhang Yongding Inventor before: Zhang Dazhun Inventor before: Zhang Qiao Inventor before: Ma Weimin |
|
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Hongtao Inventor after: Lin Jun Inventor after: Liu Yao Inventor after: Zhang Yongding Inventor after: Zhang Dazhun Inventor before: Xiong Zuying Inventor before: Wang Hongtao Inventor before: Lin Jun Inventor before: Liu Yao Inventor before: Zhang Yongding Inventor before: Zhang Dazhun Inventor before: Zhang Qiao Inventor before: Ma Weimin |
|
CB03 | Change of inventor or designer information |